NEW YORK, Jan 16 – Curagen’s $124 million toxicogenomic and pharmacogenomic deal with Bayer and its $1.34 billion agreement to collaborate on drug targets for obesity and diabetes provide Curagen with the R&D budget necessary to enhance its portfolio of genomics tools and mine the genome for blockbuster drugs, analysts and company executives said Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.